Adenovirus-mediated cytosine deaminase/5-fluorocytosine suicide gene therapy of human hepatoblastoma in vitro

Pediatric Blood and Cancer

Volumn 53, Issue 2, 2009, Pages 145-151

  Warmann, Steven W ^a   Armeanu, Sorin ^a   Heigoldt, Heike ^a,b   Ruck, Peter ^b   Vonthein, Reinhard ^a   Heitmann, Heike ^a   Seitz, Guido ^a   Lemken, Marie Luise ^a   Bitzer, Michael ^a   Fuchs, Jörg ^a   Lauer, Ulrich M ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Krankenhaus Leonberg   (Germany)

Author keywords

5 Fluorocytosine; Adenovirus vector; Cytosine deaminase; Hepatoblastoma; Suicide gene therapy

Indexed keywords

ADENOVIRUS VECTOR; CYTOSINE DEAMINASE; FLUCYTOSINE; URACIL PHOSPHORIBOSYLTRANSFERASE; ANTINEOPLASTIC AGENT; FLUOROURACIL;

ANIMAL CELL; ARTICLE; CANCER GENE THERAPY; CELL DAMAGE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFECT; DRUG EFFICACY; EMBRYO; GENE EXPRESSION; GENE FUSION; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; SUICIDE GENE; SUICIDE GENE THERAPY; TRANSGENE; TUMOR CELL; TUMOR CELL CULTURE; TUMOR CELL LINE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENE; ADENOVIRUS; FLUORESCENT ANTIBODY TECHNIQUE; GENE THERAPY; GENE VECTOR; GENETICS; LIVER TUMOR; METHODOLOGY; SUICIDE TRANSGENE;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUORESCENT ANTIBODY TECHNIQUE; FLUOROURACIL; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; TRANSDUCTION, GENETIC;

EID: 67649996061     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21956     Document Type: Article

References (36)

1. Perilongo G, Shafford E, Maibach R, et al. Risk-adapted treatment for childhood hepatoblastoma: Final report of the second study of the International Society of Paediatric Oncology - SIOPEL 2. Eur J Cancer 2004;40:411-421. (Pubitemid 38121279)
2. Klatzmann D, Valery CA, Bensimon G, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 1998;9:2595-2604.
3. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997;3:1354-1361. (Pubitemid 28011035)
4. Shand N, Weber F, Mariani L, et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiform by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 1999;10:2325-2335. (Pubitemid 29459843)
5. Adachi Y, Tamiya T, Ichikawa T, et al. Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Hum Gene Ther 2000;11:77-89. (Pubitemid 30044042)
6. Consalvo M, Mullen CA, Modesti A, et al. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 1995;154:5302-5312.
7. Ge K, Xu L, Zheng Z, et al. Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine. Int J Cancer 1997;71:675-679. (Pubitemid 27239381)
8. Kanai F, Lan KH, Shiratori Y, et al. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res 1997; 57:461-465.
9. Miller CR, Williams CR, Buchsbaum DJ, et al. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res 2002;62:773-780.
10. Ohwada A, Hirschowitz EA, Crystal RG. Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. Hum Gene Ther 1996;7:1567-1576. (Pubitemid 26302211)
11. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 1995;6:881-893.
12. Graepler F, Lemken ML, Wybranietz WA, et al. Bifunctional chimeric SuperCD suicide gene -YCD: YUPRT fusion is highly effective in a rat hepatoma model. World J Gastroenterol 2005;11:6910-6919. (Pubitemid 43126046)
13. Lal S, Lauer UM, Niethammer D, et al. Suicide genes: Past, present and future perspectives. Immunol Today 2000;21:48-54. (Pubitemid 30410699)
14. Lemken ML, Graepler F, Wolf C, et al. Fusion of HSV-1 VP22 to a bifunctional chimeric SuperCD suicide gene compensates for low suicide gene transduction efficiencies. Int J Oncol 2007;30:1153-1161.
15. Pietsch T, Fonatsch C, Albrecht S, et al. Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 1996;74:809-818. (Pubitemid 26117140)
16. Doi I. Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 1976;1:1-10.
17. Wybranietz WA, Gross CD, Phelan A, et al. Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. Gene Ther 2001;8:1654-1664. (Pubitemid 33085587)
18. Bitzer M, Armeanu S, Prinz F, et al. Caspase-8 and Apaf-1-independent caspase-9 activation in Sendai virus-infected cells. J Biol Chem 2002;277:29817-29824.
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63. (Pubitemid 14203433)
20. Koyama F, Sawada H, Hirao T, et al. Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of Escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther 2000;7:1015-1022. (Pubitemid 30483481)
21. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000;60:3813-3822.
22. Warmann SW, Armeanu S, Heitmann H, et al. Optimizing vector application for gene transfer into human hepatoblastoma cells. Pediatr Surg Int 2006;22:733-742. (Pubitemid 44341724)
23. Warmann SW, Armeanu S, Frank H, et al. In vitro gene targeting in human hepatoblastoma. Pediatr Surg Int 2006;22:16-23.
24. Sakurai F, Kawabata K, Yamaguchi T, et al. Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: Comparison of promoter activities. Gene Ther 2005;12:1424-1433. (Pubitemid 41486131)
25. Cayer MP, Drouin M, Sea SP, et al. Comparison of promoter activities for efficient expression into human B cells and haematopoietic progenitors with adenovirus Ad5/F35. J Immunol Methods 2007;322:118-127. (Pubitemid 46560590)
26. Neumunaitis J, Cunningham C, Senzer N, et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 2003;10:737-744. (Pubitemid 37243794)
27. Ortega JA, Krailo MD, Haas JE, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: A report from the Childrens Cancer Study Group. J Clin Oncol 1991;9:2167-2176.
28. Warmann S, Gohring G, Teichmann B, et al. P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors. Anticancer Res 2003;23:4607-4611. (Pubitemid 38173874)
29. Fuchs J, Wenderoth M, von Schweinitz D, et al. Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma. Cancer 1998;83:2400-2407. (Pubitemid 28533511)
30. Koyama F, Sawada H, Fuji H, et al. Adenoviral-mediated transfer of Escherichia coli uracil phosphoribosyltransferase (UPRT) gene to modulate the sensitivity of the human colon cancer cells to 5-fluorouracil. Eur J Cancer 2000;36:2403-2410. (Pubitemid 30947839)
31. Altaner C. Prodrug Cancer gene therapy. Cancer Lett 2008;270:191-201.
32. Freytag SO, Barton KN, Brown SL, et al. Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol Ther 2007;15:600-606.
33. Bertin S, Neves S, Gavelli A, et al. Cellular and molecular events associated with the antitumor response induced by the cytosine deaminase/5-fluorocytosine suicide gene therapy system in a rat liver metastasis model. Cancer Gene Ther 2007;14:858-866. (Pubitemid 47402380)
34. Hiraoka K, Kimura T, Logg CR, et al. Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Res 2007;67:5345-5353. (Pubitemid 46997274)
35. Negroni L, Samson M, Guigonis JM, et al. Treatment of colon cancer cells using the cytosine deaminase/5-fluorocytosine suicide system induces apoptosis, modulation of the proteome, and Hsp90beta phosphorylation. Mol Cancer Ther 2007;6:2747-2756. (Pubitemid 350058155)
36. Wei J, Wahl J, Knauss H, et al. Cytosine deaminase/5-fluorocytosine gene therapy and Apo2L/TRAIL cooperate to kill TRAIL-resistant tumor cells. Cancer Gene Ther 2007;14:640-651. (Pubitemid 46912036)